Clene Inc (CLNN) — Titan Protect Analysis

CLNN

Clene Inc

Healthcare · ·

$5.45

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$74M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.22

Based on estimated future earnings — lower means cheaper

Rev Growth

-81.5%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+450% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Clene Inc

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic

https://clene.com

Country: United States Employees: 76 Industry: Packaged Foods

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.475

Positive but modest risk-adjusted returns

Kelly Fraction

0.0255

Modest edge detected — smaller position warranted

Calmar Ratio

-0.085

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-6.1%

Historical annualised return based on price data

Max Drawdown

-72.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.89

Less volatile than the market — more defensive

52W High

$13.50

60% below the year high

52W Low

$3.25

68% above the year low

Avg Volume

490,344

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.25

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

82.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-13,740.0%

Profit from core operations before interest and tax

Free Cash Flow

$-11,576,125

Negative — the business is spending more than it generates

Revenue (TTM)

$134,000

Total revenue over the last 12 months

Net Income

$-33,513,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$50.00

Target Median

$30.00

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go